Interferon Advisory Board
Alexander Giaquinto, Ph.D.
Former Senior VP of Global Compliance, Schering Plough Inc.
Most recently, Dr. Giaquinto was Senior Vice President for Global Compliance at Schering-Plough Corporation, until his retirement in 1994. In more than 30 years at Schering Plough, Dr. Giaquinto held numerous positions, including Director of Regulatory Affairs and Senior Vice President of Worldwide Regulatory Affairs. During his tenure, he was instrumental in establishing the development and regulatory strategies for the approvals of 74 NDAs, 9 BLAs as well as 28 Abbreviated NDAs. He is currently a member of the American Pharmaceutical Association, the American Association of Pharmaceutical Sciences, the American Society of Clinical Pharmacology and Therapeutics, the New York Academy of Sciences as well as the Drug Information Association. Dr. Giaquinto serves on the Board of Directors for SemBioSys Genetics and the Advisory Board for Avaan Therapeutics. He holds a B.Sc. in Pharmacy from St. John’s University and a Ph.D. in Pharmaceutics from the University of Connecticut.
Douglas Goodin, M.D.
Professor of Neurology, UCSF
Dr. Goodin is an internationally renowned expert in the treatment and research of multiple sclerosis, known for his countless publications on the advancement in the understanding of multiple sclerosis. He is currently the Director of the Multiple Sclerosis Center at UCSF Medical Center as well as a Professor of Neurology at UCSF. He earned a B.Sc. in genetics and biochemistry at the University of Washington in Seattle; a Master of Sciences in molecular biology at Purdue University in Indiana; and a medical degree from the University of California, Irvine. He completed a residency in neurology at UCSF where he joined the medical center staff in 1982. Dr. Goodin’s research interests include various forms of dementia in addition to multiple sclerosis.
David A. Hafler, M.D.
Chief of Neurology, Yale-New Haven Hospital
Chair, Yale School of Medicine
Dr. Hafler is currently the chief and chair of neurology at Yale-New Haven Hospital and Yale School of Medicine. He received his B.Sc. and M.Sc. in biochemistry from Emory University and his M.D. from the University of Miami School of Medicine. Dr. Hafler received training in immunology at Rockefeller University as well as at Harvard where he joined the faculty in 1984. He is currently a member of the editorial boards for the Journal of Clinical Investigation, Cellular Immunology, Clinical Immunology, and the Journal of Neuroimmunology. He is co-founder of the Federation of Clinical Immunology Societies as well as a founding member of the International Multiple Sclerosis Genetic Consortium. His clinical research is focused on understanding the mechanism of autoimmunity with a particular interest in inflammatory CNS diseases. He currently has over 300 publications in the field of autoimmunity and immunology and has been recognized by the American Academy of Neurology with the 2010 John Dystel Prize for MS Research.
William J. Jusko, Ph.D.
Professor and Chair of Pharmaceutical Sciences, University at Buffalo
Dr. Jusko is currently the Chair of Pharmaceutical Sciences at the University of Buffalo, New York. He received his B.Sc. in Pharmaceutical Sciences (1965) and Ph.D. (1970) from the State University of New York at Buffalo. He then joined the Clinical Pharmacology Section of the Boston Veterans Administration Hospital and taught in the Pharmacology Dept. of the Boston University School of Medicine. His awards include a Fulbright-Hays Fellowship (1978), Rawls-Palmer Award from ASCPT (1987), Doctor Honoris Causae, Jagiellonian University (1987), Distinguished Service Award from ACCP (1989), and Research Achievement Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism from AAPS (1998). His research interests involve basic, clinical and theoretical pharmacokinetics and pharmacodynamics with a special emphasis on corticosteroids and immunosuppressive agents.
Ludwig Kappos, M.D.
Professor of Neurology & Clinical Neuroimmunology, University of Basel, Switzerland
Dr. Kappos obtained his M.D. and diploma of clinical psychology from the University of Wurzburg, Germany in 1980 before going on to specialize in neurology and neuroimmunology, also at the University of Wurzburg. Since 1990, he has been head of the outpatient clinic of neurology and neurosurgery and deputy chairman of the department of neurology at Kantonsspital Basel, Switzerland. In 1994 he was elected professor of neurology/clinical neuroimmunology at the medical faculty of the University of Basel. Dr. Kappos' professional interests include clinical studies in multiple sclerosis as well as other neuroinflammitory diseases, standardization of clinical assessments and the use of magnetic resonance tomography to elucidate the pathogenesis of inflammatory CNS diseases. Dr. Kappos is currently the Medical Director at Basel University Hospital in Basel, Switzerland.
Fred Lublin, M.D.
Professor of Neurology, Mount Sinai Medical Center
Chair, Clinical Advisory Committee, National MS Society, New York City Chapter
Dr. Lublin is the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis as well as a Saunders Family Professor of Neurology, both at Mount Sinai School of Medicine, New York. Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia. As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system and has published numerous scientific articles in this area. He and his colleagues were among the first in the country to study IFN β-1b, which was approved by the FDA in 1993 for treatment of relapsing-remitting MS. Using data from a survey of the international MS community, Dr. Lublin and his colleagues at the National MS Society have redefined the clinical course definitions of MS. He was chairman of the National MS Society advisory committee on clinical trials of new drugs in MS as well as the National MS Society’s Research Programs Advisory Committee.
Elliot I. Stupak, Ph.D.
Former Senior VP of Global Compliance, Schering Plough Inc.
Most recently, Dr. Stupak was Senior Vice President of Global Compliance and Quality Audits at Schering Plough Inc. During his 32 year tenure with Schering-Plough, Dr. Stupak held numerous positions including Senior Vice President of Development, with responsibility for the Biotechnology, Chemical and Pharmaceutical Development functions. Dr. Stupak also served as Team Chairman for several projects and therapy areas, including the Interferon and Oncology Teams. Dr Stupak has been active in professional organizations during his career, including PhRMA, where he served as Chairman of the Pharmaceutical Development Sub-Section. He received his B.Sc. in Pharmacy from Columbia University and his Ph.D. in Pharmaceutical Sciences from the University of Connecticut.
Former Senior VP of Global Compliance, Schering Plough Inc.
Most recently, Dr. Giaquinto was Senior Vice President for Global Compliance at Schering-Plough Corporation, until his retirement in 1994. In more than 30 years at Schering Plough, Dr. Giaquinto held numerous positions, including Director of Regulatory Affairs and Senior Vice President of Worldwide Regulatory Affairs. During his tenure, he was instrumental in establishing the development and regulatory strategies for the approvals of 74 NDAs, 9 BLAs as well as 28 Abbreviated NDAs. He is currently a member of the American Pharmaceutical Association, the American Association of Pharmaceutical Sciences, the American Society of Clinical Pharmacology and Therapeutics, the New York Academy of Sciences as well as the Drug Information Association. Dr. Giaquinto serves on the Board of Directors for SemBioSys Genetics and the Advisory Board for Avaan Therapeutics. He holds a B.Sc. in Pharmacy from St. John’s University and a Ph.D. in Pharmaceutics from the University of Connecticut.
Douglas Goodin, M.D.
Professor of Neurology, UCSF
Dr. Goodin is an internationally renowned expert in the treatment and research of multiple sclerosis, known for his countless publications on the advancement in the understanding of multiple sclerosis. He is currently the Director of the Multiple Sclerosis Center at UCSF Medical Center as well as a Professor of Neurology at UCSF. He earned a B.Sc. in genetics and biochemistry at the University of Washington in Seattle; a Master of Sciences in molecular biology at Purdue University in Indiana; and a medical degree from the University of California, Irvine. He completed a residency in neurology at UCSF where he joined the medical center staff in 1982. Dr. Goodin’s research interests include various forms of dementia in addition to multiple sclerosis.
David A. Hafler, M.D.
Chief of Neurology, Yale-New Haven Hospital
Chair, Yale School of Medicine
Dr. Hafler is currently the chief and chair of neurology at Yale-New Haven Hospital and Yale School of Medicine. He received his B.Sc. and M.Sc. in biochemistry from Emory University and his M.D. from the University of Miami School of Medicine. Dr. Hafler received training in immunology at Rockefeller University as well as at Harvard where he joined the faculty in 1984. He is currently a member of the editorial boards for the Journal of Clinical Investigation, Cellular Immunology, Clinical Immunology, and the Journal of Neuroimmunology. He is co-founder of the Federation of Clinical Immunology Societies as well as a founding member of the International Multiple Sclerosis Genetic Consortium. His clinical research is focused on understanding the mechanism of autoimmunity with a particular interest in inflammatory CNS diseases. He currently has over 300 publications in the field of autoimmunity and immunology and has been recognized by the American Academy of Neurology with the 2010 John Dystel Prize for MS Research.
William J. Jusko, Ph.D.
Professor and Chair of Pharmaceutical Sciences, University at Buffalo
Dr. Jusko is currently the Chair of Pharmaceutical Sciences at the University of Buffalo, New York. He received his B.Sc. in Pharmaceutical Sciences (1965) and Ph.D. (1970) from the State University of New York at Buffalo. He then joined the Clinical Pharmacology Section of the Boston Veterans Administration Hospital and taught in the Pharmacology Dept. of the Boston University School of Medicine. His awards include a Fulbright-Hays Fellowship (1978), Rawls-Palmer Award from ASCPT (1987), Doctor Honoris Causae, Jagiellonian University (1987), Distinguished Service Award from ACCP (1989), and Research Achievement Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism from AAPS (1998). His research interests involve basic, clinical and theoretical pharmacokinetics and pharmacodynamics with a special emphasis on corticosteroids and immunosuppressive agents.
Ludwig Kappos, M.D.
Professor of Neurology & Clinical Neuroimmunology, University of Basel, Switzerland
Dr. Kappos obtained his M.D. and diploma of clinical psychology from the University of Wurzburg, Germany in 1980 before going on to specialize in neurology and neuroimmunology, also at the University of Wurzburg. Since 1990, he has been head of the outpatient clinic of neurology and neurosurgery and deputy chairman of the department of neurology at Kantonsspital Basel, Switzerland. In 1994 he was elected professor of neurology/clinical neuroimmunology at the medical faculty of the University of Basel. Dr. Kappos' professional interests include clinical studies in multiple sclerosis as well as other neuroinflammitory diseases, standardization of clinical assessments and the use of magnetic resonance tomography to elucidate the pathogenesis of inflammatory CNS diseases. Dr. Kappos is currently the Medical Director at Basel University Hospital in Basel, Switzerland.
Fred Lublin, M.D.
Professor of Neurology, Mount Sinai Medical Center
Chair, Clinical Advisory Committee, National MS Society, New York City Chapter
Dr. Lublin is the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis as well as a Saunders Family Professor of Neurology, both at Mount Sinai School of Medicine, New York. Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia. As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system and has published numerous scientific articles in this area. He and his colleagues were among the first in the country to study IFN β-1b, which was approved by the FDA in 1993 for treatment of relapsing-remitting MS. Using data from a survey of the international MS community, Dr. Lublin and his colleagues at the National MS Society have redefined the clinical course definitions of MS. He was chairman of the National MS Society advisory committee on clinical trials of new drugs in MS as well as the National MS Society’s Research Programs Advisory Committee.
Elliot I. Stupak, Ph.D.
Former Senior VP of Global Compliance, Schering Plough Inc.
Most recently, Dr. Stupak was Senior Vice President of Global Compliance and Quality Audits at Schering Plough Inc. During his 32 year tenure with Schering-Plough, Dr. Stupak held numerous positions including Senior Vice President of Development, with responsibility for the Biotechnology, Chemical and Pharmaceutical Development functions. Dr. Stupak also served as Team Chairman for several projects and therapy areas, including the Interferon and Oncology Teams. Dr Stupak has been active in professional organizations during his career, including PhRMA, where he served as Chairman of the Pharmaceutical Development Sub-Section. He received his B.Sc. in Pharmacy from Columbia University and his Ph.D. in Pharmaceutical Sciences from the University of Connecticut.
